|
Genetic variations in the β2M/HLA-E immunomodulatory complex to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line FOLFIRI/Cetuximab: Data from the phase III FIRE-3 trial. |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bayer; Lilly; Merck KGaA; Roche; Sanofi; Sirtex Medical |
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Lilly; Merck KGaA; Roche; Sanofi |
Travel, Accommodations, Expenses - Amgen; Bayer; Lilly; Merck KGaA; Roche; Sanofi; Sirtex Medical |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Amgen; Bayer |
|
|
Consulting or Advisory Role - bioTheranostics; Merrion |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Baxalta; Celgene; Merck; Roche; Sanofi; Sirtex Medical |
Consulting or Advisory Role - Amgen; Baxalta; Boehringer Ingelheim; Celgene; Merck; Roche; Sanofi; Sirtex Medical |
Research Funding - Amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); IntegraGen (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); Sirtex Medical (Inst); Taiho Pharmaceutical (Inst) |
Travel, Accommodations, Expenses - Amgen; Baxalta; Merck; Roche; Sirtex Medical |
|
|
Honoraria - Bayer; Boehringer Ingelheim; Merck Serono; Roche |
Consulting or Advisory Role - Bayer; Merck Serono; Pfizer; Roche |
Travel, Accommodations, Expenses - Bayer; Merck Serono; Roche |